### v1.1.0 release
The IDs of the data elements listed in the table below were modified to align with the notation used for all the other data elements  (_"Process ID".“DE”.“Running number”_).

| Old ID | Data element label | New ID |
| --- | --- | --- |
| IMMZ.D1.DE.8 | Completed the primary vaccination series | IMMZ.D.DE.203 |
| IMMZ.D1.DE.10 | HIV status | IMMZ.D.DE.204 |
| IMMZ.D1.DE.11 | HIV-positive | IMMZ.D.DE.205 |
| IMMZ.D1.DE.12 | HIV-negative | IMMZ.D.DE.206 |
| IMMZ.D1.DE.13 | Unknown | IMMZ.D.DE.207 |
| IMMZ.D1.DE.15 | Preterm birth | IMMZ.D.DE.208 |
| IMMZ.D1.DE.16 | Immunocompromised | IMMZ.D.DE.209 |
| IMMZ.D1.DE.17 | Currently on ART | IMMZ.D.DE.210 |
| IMMZ.D1.DE.29 | Birth weight in grams | IMMZ.D.DE.211 |
| IMMZ.D1.DE.35 | Type of poliovirus dose | IMMZ.D.DE.212 |
| IMMZ.D1.DE.36 | IPV | IMMZ.D.DE.213 |
| IMMZ.D1.DE.37 | bOPV | IMMZ.D.DE.214 |
| IMMZ.D1.DE.49 | ART start date | IMMZ.D.DE.215 |
| IMMZ.D1.DE.52 | Type of JE dose | IMMZ.D.DE.216 |
| IMMZ.D1.DE.53 | Inactivated Vero cell-derived vaccine | IMMZ.D.DE.217 |
| IMMZ.D1.DE.54 | Live attenuated vaccine | IMMZ.D.DE.218 |
| IMMZ.D1.DE.55 | Live recombinant vaccine | IMMZ.D.DE.219 |
| IMMZ.D1.DE.56 | Type of TBE dose | IMMZ.D.DE.220 |
| IMMZ.D1.DE.57 | FSME-Immun | IMMZ.D.DE.221 |
| IMMZ.D1.DE.58 | Encepur | IMMZ.D.DE.222 |
| IMMZ.D1.DE.59 | TBE-Moscow | IMMZ.D.DE.223 |
| IMMZ.D1.DE.60 | EnceVir | IMMZ.D.DE.224 |
| IMMZ.D1.DE.61 | Type of typhoid dose | IMMZ.D.DE.225 |
| IMMZ.D1.DE.62 | Typbar-TCV | IMMZ.D.DE.226 |
| IMMZ.D1.DE.63 | ViPS | IMMZ.D.DE.227 |
| IMMZ.D1.DE.64 | Ty21a | IMMZ.D.DE.228 |
| IMMZ.D1.DE.65 | Type of cholera dose | IMMZ.D.DE.229 |
| IMMZ.D1.DE.66 | WC vaccine | IMMZ.D.DE.230 |
| IMMZ.D1.DE.67 | WC-rBS vaccine | IMMZ.D.DE.231 |
| IMMZ.D1.DE.68 | Type of meningococcal dose | IMMZ.D.DE.232 |
| IMMZ.D1.DE.69 | MenA conjugate vaccine (5µg) | IMMZ.D.DE.233 |
| IMMZ.D1.DE.70 | Monovalent MenC conjugate | IMMZ.D.DE.234 |
| IMMZ.D1.DE.71 | Quadrivalent conjugate | IMMZ.D.DE.235 |
| IMMZ.D1.DE.72 | Age in months when client received first meningococcal dose | IMMZ.D.DE.236 |
| IMMZ.D1.DE.73 | Type of hepatitis A dose | IMMZ.D.DE.237 |
| IMMZ.D1.DE.74 | Live attenuated hepatitis A vaccine | IMMZ.D.DE.238 |
| IMMZ.D1.DE.75 | Inactivated hepatitis A vaccine | IMMZ.D.DE.239 |
| IMMZ.D1.DE.76 | VNA level | IMMZ.D.DE.240 |
| IMMZ.D1.DE.77 | Dengue serostatus | IMMZ.D.DE.241 |
| IMMZ.D1.DE.81 | Date when primary vaccination series was completed | IMMZ.D.DE.242 |
| IMMZ.D1.DE.84 | Type of TB infection test performed | IMMZ.D.DE.243 |
| IMMZ.D1.DE.85 | IGRA | IMMZ.D.DE.244 |
| IMMZ.D1.DE.86 | TST | IMMZ.D.DE.245 |
| IMMZ.D1.DE.87 | TB infection test result | IMMZ.D.DE.246 |
| IMMZ.D1.DE.88 | Positive | IMMZ.D.DE.247 |
| IMMZ.D1.DE.89 | Negative | IMMZ.D.DE.248 |
| IMMZ.D1.DE.93 | Immunologically stable | IMMZ.D.DE.249 |
| IMMZ.D1.DE.94 | Clinically well | IMMZ.D.DE.250 |
| IMMZ.D1.DE.96 | High risk of pneumococcal infection | IMMZ.D.DE.251 |
| IMMZ.D1.DE.97 | Polysaccharide vaccine | IMMZ.D.DE.252 |
| IMMZ.D1.DE.98 | Risk of occupational exposure to rabies virus | IMMZ.D.DE.253 |
| IMMZ.D1.DE.99 | Type of hepatitis B dose | IMMZ.D.DE.254 |
| IMMZ.D1.DE.100 | Hepatitis B monovalent vaccine | IMMZ.D.DE.255 |
| IMMZ.D1.DE.101 | Hepatitis B combination vaccine | IMMZ.D.DE.256 |
| IMMZ.D1.DE.102 | Completed the booster series | IMMZ.D.DE.257 |
| IMMZ.D1.DE.103 | Type of dose | IMMZ.D.DE.258 |
| IMMZ.D1.DE.104 | Primary series | IMMZ.D.DE.259 |
| IMMZ.D1.DE.105 | Dose 0 | IMMZ.D.DE.260 |
| IMMZ.D1.DE.106 | Supplementary dose | IMMZ.D.DE.261 |
| IMMZ.D1.DE.107 | Booster dose | IMMZ.D.DE.262 |
| IMMZ.D1.DE.109 | Birth dose | IMMZ.D.DE.263 |
| IMMZ.D1.DE.110 | Positive | IMMZ.D.DE.264 |
| IMMZ.D1.DE.111 | Negative | IMMZ.D.DE.265 |
| IMMZ.D1.DE.112 | Unknown | IMMZ.D.DE.266 |

### v1.0.0 release

This is the first release, therefore there are no changes to be mentioned here.